Is CRISPR Therapeutics (NASDAQ:CRSP) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating CRISPR Therapeutics at current levels.
CASGEVY is the proof, but the in-vivo cardiovascular pipeline is where CRSP either becomes a $30B story or breaks.
Where CRSP is headed
By the back half of 2027, CRISPR Therapeutics looks like two different companies stitched together. The CASGEVY side is finally producing real money, not headlines. Vertex is doing the heavy lifting on commercial activation, authorised treatment centres have crossed roughly 75 globally, and the patient backlog that took agonising quarters to convert is now moving through manufacturing at a pace that puts CRSP's share of the economics on a $400-600M annual run-rate by 2028. That alone, modelled honestly, justifies somewhere in the $50-70 share range. It is not the reason to own this.
Read the full Compass Direction on CRSP
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $51.48).
See the full CRSP analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is CRISPR Therapeutics (NASDAQ:CRSP) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating CRISPR Therapeutics at current levels. CASGEVY is the proof, but the in-vivo cardiovascular pipeline is where CRSP either becomes a $30B story or breaks.
What is CRSP's Compass Score?
CRISPR Therapeutics scores 86/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for CRSP?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the CRSP page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.